|
Item 1.01
|
Entry into Material
Definitive Agreements
|
The Exchange Agreement
On August 1, 2018, Pernix Therapeutics
Holdings, Inc. (“Pernix” or the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”)
by and among Pernix and
certain holders (each, an “Exchange
Holder,” and collectively the “Exchange Holders”) of Pernix’s outstanding 12% Senior Secured Notes due
2020 (the “Senior Secured Notes”). The Exchange Agreement governs the issuance by the Company of shares of its common
stock (the “Common Stock”) and shares of a newly created class of convertible preferred stock, the terms of which
are described below (the “Preferred Stock”) to the Exchange Holders in exchange for Senior Secured Notes held by such
Exchange Holders (collectively, the “Exchange Transactions”). Subject to the satisfaction of certain closing conditions,
the Exchange Transactions are expected to close on August 1, 2018, and include:
|
1.
|
The
exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes
by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued
and unpaid interest on the Senior Secured Notes; and
|
|
2.
|
The
exchange of $8 million aggregate principal amount of Senior Secured Notes plus $100,000
of accrued and unpaid interest by the Exchange Holders for 81,000 shares of the Preferred
Stock and the payment of $380,000 for accrued and unpaid interest on the Senior Secured
Notes exchanged for Preferred Stock.
|
In addition, the Exchange Agreement
permits additional exchanges, at the option of the Exchange Holders, of up to $65.1 million aggregate principal amount of Senior
Secured Notes, plus accrued and unpaid interest, until February 1, 2020.
The Exchange Transactions are
subject to a number of customary closing conditions, including the Common Stock being eligible for clearance through the facilities
of DTC, the Common Stock and Preferred Stock being eligible for immediate resale pursuant to Rule 144 under the Securities Act,
and the Common Stock being approved for listing, subject to notice of issuance, on the Nasdaq Global Market. The parties to the
Exchange Agreement have made certain customary representations and warranties.
Convertible Preferred Stock
At the closing of the Exchange
Transactions, the Company will file with the State Department of Assessments and Taxation of Maryland an Articles Supplementary
(the “Articles Supplementary”) to the Company’s Articles of Incorporation setting out the form and terms of
the Preferred Stock.
Exchange Holders of Preferred
Stock will have the right to convert their shares of Preferred Stock, in whole or in part, at any time on or after August 1, 2018
(the “Initial Issue Date”). The Company will have the right, at its option, to automatically convert all shares of
Preferred Stock, subject to the satisfaction of certain specified conditions. Upon any conversion of an Exchange Holder’s
Preferred Stock, Pernix will deliver shares of Common Stock, calculated by multiplying the number of shares of Preferred Stock
by 41.841 shares of Common Stock per share of
Preferred Stock (the “Conversion
Rate”). The Conversion Rate is equal to the number of shares of Common Stock, such that the Preferred Stock shall be convertible
into Common Stock at a price $0.01 above the consolidated closing bid price on the Initial Issue Date, which was $2.39.
Subsequent to the Initial Issue
Date, an Exchange Holder shall not be able to convert Preferred Stock into Common Stock to the extent that the Common Stock held
by such Exchange Holder and its affiliates would exceed 4.985% of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock.
Moreover, at any time on or after
the Initial Issue Date, the Company will have the right to redeem the Preferred Stock, in whole or in part, at a redemption price
equal to 100% of the liquidation preference of the shares to be redeemed, plus any accrued and unpaid dividends. Except as required
by law or the Articles Supplementary, the Exchange Holders of Preferred Stock have no voting rights (other than with respect to
certain matters regarding the Preferred Stock).
In accordance with the Articles
Supplementary, the Company will not authorize, declare or pay regular or special dividends or other distributions (whether in
the form of cash, shares, indebtedness or any other property or asset, but excluding any purchase, redemption or other acquisition
of shares) on the shares of the Common Stock, unless simultaneously with the authorization, declaration or payment, it authorizes,
declares or pays, as applicable, dividends or other distributions on the Preferred Stock.
Amended ABL Facility and
Term Facility
On August 1, 2018 Pernix entered
into an amendment (the “ABL Amendment”) of the asset-based revolving credit facility agreement by and among Pernix,
the guarantors and lenders party thereto and Cantor Fitzgerald Securities, as agent (the “ABL Facility”), as well
as an amendment (the “Term Amendment” and together with the ABL Amendment, the “Amendments”) to the delayed
draw term loan facility by and among Pernix Ireland Pain Designated Activity Company (“PIP DAC”), the lenders party
thereto and Cantor Fitzgerald Securities, as agent (the “Term Facility” and together with the ABL Facility”,
the “Credit Facilities”). The Amendments were made to permit the exchange of the Senior Secured Notes into the Common
Stock in the Exchange Transaction and Equitization Transaction, and to amend certain other terms of the Credit Facilities, including
(i) a reduction in the commitments under the ABL Facility from $40,000,000 to $32,500,000, (ii) certain changes to the borrowing
base calculation under the ABL Facility, which will permit the Company, among other things, to include certain recently acquired
assets in the calculation of the borrowing base and (iii) changes to the interest payment provisions under the Term Facility increasing
the minimum percentage of interest that must be paid in cash to 6.00% and (iv) changes to permit the use of subsequent draws under
the Term Facility for working capital or other general corporate purposes.
The effectiveness of the Amendments
is conditioned on the closing of the Equitization Transaction described below.
The Equitization Exchange
Agreements
On August 1, 2018, Pernix entered
into separate Equitization Exchange Agreements (the “Equitization Exchange Agreements”)
by
and among Pernix and
certain holders (each, an “Equitization Holder,” and collectively the “Equitization
Holders”) of Pernix’s Senior Secured Notes. The Equitization Exchange Agreements provide that the Company will issue
650,241 shares of its Common Stock in exchange for approximately $1.5 million aggregate principal amount of Senior Secured Notes
held by such Equitization Holders (the “Equitization Transaction”). Subject to the satisfaction of certain closing
conditions, the Equitization Transaction is expected to close on August 1, 2018.
The Equitization Transaction
is subject to a number of customary closing conditions, including the Common Stock being eligible for clearance through the facilities
of DTC, the Common Stock being eligible for immediate resale pursuant to Rule 144 under the Securities Act, and the Common Stock
being approved for listing, subject to notice of issuance, on the Nasdaq Global Market. The parties to the Equitization Exchange
Agreements have made certain customary representations and warranties.
The Exchange Agreement, the Articles
Supplementary, the Amendments, and the Exchange Equitization Agreement (collectively, the “Agreements”) are filed
as exhibits to this Current Report on Form 8-K and are incorporated herein by reference. This summary of the Agreements does not
purport to be complete and is qualified in its entirety by reference to the full text of the Agreements attached as exhibits hereto.
The summary of the Agreements and the summaries of the Exchange Transaction and Equitization Transaction contemplated thereby
and contained herein are not intended to provide any other factual information about the Company or its subsidiaries. Any representations,
warranties and covenants contained in the Agreements were made solely for purposes of the transactions governed thereby and as
of specific dates and solely for the benefit of the parties thereto, may be subject to limitations agreed upon by the contracting
parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the
parties instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting
parties that differ from those applicable to security holders. The Company’s other security holders are not third-party
beneficiaries under any of the Agreements and should not rely on the representations, warranties and covenants or any descriptions
thereof as characterizations of the actual state of facts or condition of the Company or its subsidiaries. Moreover, information
concerning the subject matter of the representations and warranties may change after the date of the Agreements, which subsequent
information may or may not be fully reflected in the Company’s public disclosures.